Preview

User

Not a user? Register with this site Forgot your password?

Problems of Endocrinology

Advanced search

Modern strategies for the treatment of childhood obesity

https://doi.org/10.14341/probl13208

Abstract

The prevalence of obesity and related metabolic disorders in children and adolescents in the Russian Federation is steadily increasing, which requires healthcare professionals to search for new methods of treatment and prevention. The treatment of childhood obesity should be based on a comprehensive approach, including diet therapy, increased physical activity, behavioral therapy and psychological support. To increase the effectiveness of the formation of new eating habits and proper eating behavior, as well as to increase the adherence of children and adolescents to treatment, drug therapy of obesity is used, aimed primarily at reducing appetite. Considering the efficacy and safety of glucagon-like peptide 1 analog (Liraglutide) in adolescents, as well as a small number of gastrointestinal side effects, this drug is promising in the complex treatment of childhood obesity. This review presents an analysis of the literature on non-medicated and drug-based methods of treatment of childhood obesity.

About the Authors

O. V. Vasyukova
Endocrinology Research Centre
Russian Federation

Olga V. Vasyukova - MD

11 Dm. Ulyanova street, 117036, Moscow

SPIN-код: 6432-3934
Competing Interests:

None



P. L. Okorokov
Endocrinology Research Centre
Russian Federation

Pavel L. Okorokov - MD

11 Dm. Ulyanova street, 117036, Moscow

SPIN-код: 6989-2620
Competing Interests:

None



O. B. Bezlepkina
Endocrinology Research Centre
Russian Federation

Olga B. Bezlepkina - MD

11 Dm. Ulyanova street, 117036, Moscow

SPIN-код: 3884-0945
Competing Interests:

None



References

1. World Health Organization. Noncommunicable Diseases Progress Monitor. 2022. 233 p.

2. World Health Organization [Internet]. Ozhirenie i izbytochnyj ves. (In Russ.). Доступно по: https://www.who.int/newsroom/ fact-sheets/detail/obesity-and-overweight. Ссылка активна на 20.12.2022.

3. Twig G, Yaniv G, Levine H, et al. Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood. N Engl J Med. 2016;374(25):2430-2440. doi: https://doi.org/10.1056/NEJMoa1503840

4. Franks PW, Hanson RL, Knowler WC, et al. Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med. 2010;362(6):485-493. doi: https://doi.org/10.1056/NEJMoa0904130

5. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2450. doi: https://doi.org/10.1056/NEJMsa1909301

6. Frühbeck G, Busetto L, Dicker D, et al. The ABCD of obesity: An EASO position statement on a diagnostic term with clinical and scientific implications. Obes Facts. 2019;12(2):131-136. doi: https://doi.org/10.1159/000497124

7. World Health Organization. Report on the fifth round of data collection, 2018–2020: WHO European Childhood Obesity Surveillance Initiative (COSI). 2022. 70 р.

8. Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011;365(20):1876-1885. doi: https://doi.org/10.1056/NEJMoa1010112

9. Bjerregaard LG, Jensen BW, Ängquist L, et al. Change in overweight from childhood to early adulthood and risk of type 2 diabetes. N Engl J Med. 2018;378(14):1302-1312. doi: https://doi.org/10.1056/NEJMoa1713231

10. Lavelle H V., Mackay DF, Pell JP. Systematic review and metaanalysis of school-based interventions to reduce body mass index. J Public Health (Bangkok). 2012;34(3):360-369. doi: https://doi.org/10.1093/pubmed/fdr116

11. Sbruzzi G, Eibel B, Barbiero SM, et al. Educational interventions in childhood obesity: a systematic review with meta-analysis of randomized clinical trials. Prev Med. 2013;56(5):254-264. doi: https://doi.org/10.1016/j.ypmed.2013.02.024

12. Ho M, Garnett SP, Baur LA, et al. Impact of dietary and exercise interventions on weight change and metabolic outcomes in obese children and adolescents: a systematic review and metaanalysis of randomized trials. JAMA Pediatr. 2013;167(8):759-768. doi: https://doi.org/10.1001/jamapediatrics.2013

13. Colquitt JL, Loveman E, O’Malley C, et al. Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in preschool children up to the age of 6 years. Cochrane Database Syst Rev. 2016;34(3):360-369. doi: https://doi.org/10.1002/14651858.CD012105

14. Kittel R, Brauhardt A, Hilbert A. Cognitive and emotional functioning in binge-eating disorder: A systematic review. Int J Eat Disord. 2015;48(6):535-554. doi: https://doi.org/10.1002/eat.22419

15. Sidorov А. The typology of psychological features in patients with alimentary obesity. Psychological Studies. 2012;5(21):10. (In Russ.). doi: https://doi.org/10.54359/ps.v5i21.798

16. Ruiz LD, Zuelch ML, Dimitratos SM, Scherr RE. Adolescent Obesity: Diet Quality, Psychosocial Health, and Cardiometabolic Risk Factors. Nutrients. 2019;12(1):43. doi: https://doi.org/10.3390/nu12010043

17. Wilfley DE, Saelens BE, Stein RI, et al. Dose, content, and mediators of family-based treatment for childhood obesity: a multi-site randomized clinical trial. JAMA Pediatr. 2017;171(12):1151-1159. doi: https://doi.org/10.1001/jamapediatrics.2017.2960

18. Peterkova AV, Bezlepkina OB, Vasiukova OV, et al. Ozhirenie u detei. Klinicheskie rekomendatsii. Moscow: Ministerstvo zdravookhraneniia Rossiiskoi Federatsii; 2021. (In Russ.).

19. Pyr’eva EA, Gmoshinskaia MV, Safronova AI, et al. Zdorovoe pitanie shkol’nika. Posobie dlia roditelei. Moscow: FGBUN «FITs pitaniia i biotekhnologii»; 2021. (In Russ.).

20. Woodcock J, Franco OH, Orsini N, Roberts I. Non-vigorous physical activity and all-cause mortality: systematic review and metaanalysis of cohort studies. Int J Epidemiol. 2011;40(1):121-138. doi: https://doi.org/10.1093/ije/dyq104

21. World Health Organization. Global’nye rekomendatsii po fizicheskoi aktivnosti dlia zdorov’ia. Moscow; 2010. (In Russ.).

22. WHO Regional Office for Europe. Growing Up Unequal: Gender and Socioeconomic Differences in Young People’s Health and Well-being—Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2013/2014. Survey Copenhagen: WHO Regional Office for Europe; 2015.

23. Konstabel K, Veidebaum T, Verbestel V, et al. Objectively measured physical activity in European children: the IDEFICS study. Int J Obes (Lond). 2014;38(S2):S135-143. doi: https://doi.org/10.1038/ijo.2014.144

24. WHO. Guidelines on physical activity, sedentary behavior and sleep for children under 5 years of age. Geneva: World Health Organization; 2019.

25. O’Connor EA, Evans CV, Burda BU, et al. Screening for obesity and intervention for weight management in children and adolescents: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017;317(23):2427-2444. doi: https://doi.org/10.1001/jama.2017.0332

26. Graaf Cd, Donnelly D, Wootten D, et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes. Pharmacol Rev. 2016;68(4):954-1013. doi: https://doi.org/10.1124/pr.115.011395

27. Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex — linking immunity and metabolism. Nat Rev Endocrinol. 2012;8(12):743-754. doi: https://doi.org/10.1038/nrendo.2012.189

28. Takai S, Yasumatsu K, Inoue M, et al. Glucagon-like peptide-1 is specifically involved in sweet taste transmission. FASEB J. 2015;29(6):2268-2280. doi: https://doi.org/10.1096/fj.14-265355

29. Thiebaud N, Llewellyn-Smith IJ, Gribble F, et al. The incretin hormone glucagon-like peptide 1 increases mitral cell excitability by decreasing conductance of a voltage-dependent potassium channel. J Physiol. 2016;594(10):2607-2628. doi: https://doi.org/10.1113/JP272322

30. Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59(5):954-965. doi: https://doi.org/10.1007/s00125-016-3874-y

31. van Can J, Sloth B, Jensen CB, et al. Effects of the oncedaily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2013;38(6):784-793. doi: https://doi.org/10.1038/ijo.2013.162

32. Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117-2128. doi: https://doi.org/10.1056/NEJMoa1916038

33. Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14-19. doi: https://doi.org/10.1080/00325481.2021.2002616

34. Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, et al. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. Diabetes Ther. 2019;10(1):5-19. doi: https://doi.org/10.1007/s13300-018-0535-9

35. Patel S, Miles K. What are the gastrointestinal adverse effects of the glucagon-like peptide 1 receptor agonists, and how should they be managed? [cited 01.11.2022]. Available from: https://illinoisadvance.com/what-are-gastrointestinal-adverse-effects-glucagon-peptide-1-receptor-agonists-and-how-should-they-be-managed/


Supplementary files

Review

For citations:

Vasyukova O.V., Okorokov P.L., Bezlepkina O.B. Modern strategies for the treatment of childhood obesity. Problems of Endocrinology. 2022;68(6):131-136. (In Russ.) https://doi.org/10.14341/probl13208

Views: 6110


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)

11, Dm. Ul’yanova str., Moscow, Russian Federation, 117292

Processing of personal data
supported by NEICON (Elpub lab)